Celularity (CELU) Non-Current Deffered Revenue (2019 - 2025)
Celularity (CELU) posted quarterly Non-Current Deffered Revenue of $2.8 million for Q4 2025, up 2.75% year-over-year from $2.7 million in Q4 2024, and up 1.27% quarter-over-quarter from $2.8 million in Q3 2025.
Celularity (CELU) Non-Current Deffered Revenue (2019 - 2025) Analysis & Trends
Celularity (CELU) has reported Non-Current Deffered Revenue for 7 consecutive years, with $2.8 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Non-Current Deffered Revenue rose 2.75% year-over-year to $2.8 million; the TTM figure through Dec 2025 stood at $2.8 million (up 2.75% YoY), while the FY2025 annual figure was $2.8 million, up 2.75% from the prior year.
- Non-Current Deffered Revenue grew to $2.8 million in Q4 2025 per CELU's latest filing, from $2.8 million in the prior quarter.
- Across five years, Non-Current Deffered Revenue topped out at $10.8 million in Q1 2021 and bottomed at $1.8 million in Q3 2021.
- Historically, Non-Current Deffered Revenue has averaged $3.4 million across 5 years, with a median of $2.7 million in 2024.
- Annual changes were most pronounced in 2021 — Non-Current Deffered Revenue plunged 83.51% — and 2023, when it surged 46.18%.
- Celularity's Non-Current Deffered Revenue stood at $1.9 million in 2021, then rose by 18.6% to $2.2 million in 2022, then surged by 43.58% to $3.2 million in 2023, then declined by 14.5% to $2.7 million in 2024, then rose by 2.75% to $2.8 million in 2025.
- Business Quant data shows CELU's Non-Current Deffered Revenue at $2.8 million in Q4 2025, $2.8 million in Q3 2025, and $2.9 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 147.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Celularity | 20.99 Mn | 14.82 Mn | -3.27 Mn | 2.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.80 Mn |
| Sep 30, 2025 | 2.76 Mn |
| Jun 30, 2025 | 2.87 Mn |
| Mar 31, 2025 | 2.80 Mn |
| Dec 31, 2024 | 2.72 Mn |
| Sep 30, 2024 | 2.64 Mn |
| Jun 30, 2024 | 3.44 Mn |
| Mar 31, 2024 | 3.27 Mn |
| Dec 31, 2023 | 3.19 Mn |
| Sep 30, 2023 | 3.10 Mn |
| Jun 30, 2023 | 2.36 Mn |
| Mar 31, 2023 | 2.33 Mn |
| Dec 31, 2022 | 2.22 Mn |
| Sep 30, 2022 | 2.12 Mn |
| Jun 30, 2022 | 2.00 Mn |
| Mar 31, 2022 | 1.93 Mn |
| Dec 31, 2021 | 1.87 Mn |
| Sep 30, 2021 | 1.78 Mn |
| Jun 30, 2021 | 10.81 Mn |
| Mar 31, 2021 | 10.81 Mn |